Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,995.00-1.13%ETH$2,462.70-0.07%GOLD$4,383.50-0.54%OIL$98.87-3.52%
Smart Investors Daily
EA

NASDAQ · EAR

Eargo, Inc.

Healthcare · Medical - Devices

$2.57

Down-$0.11 (-4.10%)

Updated Sep 11, 2026, 11:00 AM

SID Score

—

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
53.36M
P/E ratio
-0.06
Dividend yield
0.00%
52-week range
— – —
Volume
201.27K
Avg. volume
22.91K

Price performance

EAR price history

1M range · 0 trading sessions · Daily adjusted prices

EAR does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest EAR news

The latest Smart Investors Daily articles mentioning EAR.

Stock researchCompany · Overview

EAR research

Overview

Company profile and research snapshot.

Company profile

Eargo, Inc., a medical device company, engages in enhancing the quality of life of people with hearing loss in the United States. The company markets and sells hearing aids. It sells its products direct-to-consumer and through omni-channel. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc. was incorporated in 2010 and is headquartered in San Jose, California.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Sell
Average target
$2.04
Implied upside
—
Analysts
8
EAR recent ratings
DateFirmRatingTarget
Sep 23, 2021William BlairMarket Perform—
Sep 23, 2021Wells FargoEqual-Weight—
Sep 23, 2021JP MorganUnderweight—
May 13, 2021Wells FargoOverweight—
Nov 10, 2020JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

GlobeNewswire Inc. · Nov 1, 2023

Eargo Celebrates 1-Year Anniversary of FDA's Over-the-Counter (OTC) Hearing Aid Regulations, Driving a New Era of Accessibility and Innovation

SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR) (“Eargo”) celebrates the one-year anniversary of the creation of an over-the-counter (OTC) hearing aid category in the US. This important advancement by the US Food & Drug Administration (FDA), following a bipartisan mandate from Congress, was meant to reduce costs, increase competition, improve access, and drive innovation in the hearing aid category, resulting in more widespread adoption of hearing technology. This firmly aligns with Eargo’s founding mission.

GlobeNewswire Inc. · Oct 26, 2023

Eargo Expands Relationship with Best Buy, Growing In-Store Presence to Over 500 Locations

SAN JOSE, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced an expansion of its relationship with Best Buy. Eargo devices are now on display in more than 500 Best Buy stores, marking another step in Eargo’s retail journey. Approximately 250 of these Best Buy locations will carry Eargo 5–an over-the-counter, FDA-cleared and self-fitting hearing aid–allowing customers to see Eargo’s virtually invisible design and purchase in store. Additionally, customers can explore Eargo's full assortment of hearing aids on BestBuy.com. Through this expansion, Eargo continues its mission to make hearing wellness more accessible, reaching more people where they are across the country.

Zacks Investment Research · Jul 27, 2023

DexCom (DXCM) Beats Q2 Earnings and Revenue Estimates

DexCom (DXCM) delivered earnings and revenue surprises of 54.55% and 4.10%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By